Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Insider transactions by Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO). The Form 4 reports two open-market disposals on 08/28/2025, selling 686.571 shares and 724.767 shares at $489.74 per share. After those sales the filing shows beneficial ownership reported as approximately 114,487.052 and 113,762.285 shares (direct holdings). The filing also discloses indirect holdings of 11,300 shares through the Alison Casper 2020 Irrevocable Trust, 14,608 shares via Floral Park Associates, Inc., and 5,000 shares via the MNC 2020 Irrevocable Trust. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Casper on 09/02/2025.
Thermo Fisher (TMO) Form 4 — insider dispositions by Sr. VP & CFO Stephen Williamson. The filing reports four open-market sales on 08/28/2025 totaling 783.273 shares at $489.74 per share. After these transactions, Williamson directly held 32,320.193 shares and is noted as indirectly beneficially owning 12,674 shares through a SLAT, with a disclaimer that he disclaims beneficial ownership except for any pecuniary interest. The form is signed by an attorney-in-fact on 09/02/2025.
Michael D. Shafer, Executive Vice President of Thermo Fisher Scientific, filed a Form 4 disclosing four dispositions of the issuer's common stock on 08/28/2025. Each transaction is reported with Transaction Code F and a per-share price of $489.74. The reported share decreases are 145.051, 162.457, 176.478 and 114.106 shares, leaving a final beneficial ownership of 18,730.8026 shares after the last reported sale. The filing notes inclusion of 49.871 shares acquired under the company employee stock purchase plan on May 15, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Shafer on 09/02/2025. The document identifies Mr. Shafer as an officer (Executive Vice President) of the issuer.
Frederick M. Lowery, Executive Vice President of Thermo Fisher Scientific (TMO), reported multiple disposals of common stock on 08/28/2025 at a price of $489.74 per share. The Form 4 shows four separate disposition entries totaling 667.718 shares disposed (175.028 + 187.116 + 186.632 + 118.942) and remaining direct beneficial ownership reported in fractional amounts (14,860.0624; 14,672.9464; 14,486.3144; 14,367.3724 across lines). The filing also reports indirect holdings of 1,174.88 shares through a 401(k) plan and 5.036 shares via a limited liability company, with a disclaimer of beneficial ownership for the LLC position.
Michel Lagarde, Executive Vice President & COO of Thermo Fisher Scientific (TMO), reported multiple open-market sales on 08/28/2025. The Form 4 shows four dispositions totaling 961.203 shares sold at $489.74 per share (transaction code F). After these transactions, the report indicates Mr. Lagarde beneficially owns 23,479.909 shares. The filing was signed on behalf of Mr. Lagarde by an attorney-in-fact on 09/02/2025.
Joseph R. Holmes, VP & Chief Accounting Officer of Thermo Fisher Scientific (TMO), reported several equity transactions on Form 4 dated 08/28/2025–08/29/2025. The filing shows multiple dispositions on 08/28/2025 at $489.74 per share (totaling reductions of 37.977 shares when summing 8.512, 10.567, 10.86 and 7.045) and additional transactions on 08/29/2025 including an acquisition of 385 shares at $253.99 and two open-market sales of 100 shares at $492.615 and 285 shares at $492.633. Following these transactions, Holmes beneficially owned 2,318.9815 shares directly. The filing notes 54.846 shares were acquired under the issuer’s employee stock purchase plan on May 15, 2025, and that the 385-share option vested in four installments in 2020–2023.
Gianluca Pettiti, listed as Executive Vice President of Thermo Fisher Scientific (TMO), reported multiple dispositions of Common Stock on 08/28/2025. Four separate line items show sales (transaction code F) totaling 814.702 shares at $489.74 per share, with post-transaction beneficial ownership reported as 21,552.223 to 22,167.238 shares across the entries. The Form 4 is signed by an attorney-in-fact on 09/02/2025. The filing provides name, address, role, transaction dates, codes, quantities, price, and resulting ownership figures.
Thermo Fisher Scientific insider transaction: This Form 4 shows Lisa P. Britt, Sr. VP and Chief HR Officer, reported four dispositions of Thermo Fisher common stock on 08/28/2025. Each line records a transaction code "F" disposing of 81.229, 87.514, 96.7, and 63.339 shares at $489.74 per share. The reported beneficially owned share totals after each disposition are 16,142.357, 16,054.843, 15,958.143, and 15,894.804 shares, respectively. The form is signed by an attorney-in-fact on behalf of Ms. Britt on 09/02/2025. The filing is a routine Section 16 disclosure documenting insider sales; no derivative transactions or additional explanatory text are provided.
Thermo Fisher Scientific Inc. has completed its acquisition of Solventum Corporation’s purification and filtration business. The company announced the closing in a press release dated September 2, 2025, following the earliest event date of September 1, 2025.
The acquired operations focus on purification and filtration technologies, which fit within Thermo Fisher’s broader scientific and laboratory solutions portfolio. Details such as purchase price, financing, and expected financial impact are not included in this summary document but are referenced in the attached press release.
Thermo Fisher Scientific (TMO) Form 144 notice for a proposed sale of common stock. The filing shows 385 shares to be sold through Fidelity Brokerage Services with an approximate aggregate market value of $189,661.91 and an approximate sale date of 08/29/2025 on the NYSE. The filing reports 377,612,121 shares outstanding. The securities were listed as acquired on 08/29/2025 by exercise of an option granted 02/26/2019, and payment is indicated as cash. Several identifying fields such as the filer CIK/CCC and the named person for whose account the securities are to be sold are blank in the provided text, and no sales in the past three months are reported.